首页> 外文OA文献 >PCN11 An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer

【2h】

PCN11 An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer

机译：PCN11依维莫司（Afinitor®）和氟维酯药在激素受体阳性（HR +）HER2阴性（HER2-）晚期或转移性乳腺癌治疗中的间接治疗比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Chandiwana D.; Vieira J.; Granville J.; McCool R.; Fleetwood K.;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacyand Safety of Palbociclib (PAL) PUS Fulvestrant (F) by Geographic Region in Women with Endocrine-Resistant Hormone Receptor-Positive (HR+), Human Epiderman Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC) from Paloma-3 [J] . Nadia Harbeck, Marco Colleoni, Angela Demichele, The Breast : . 2017,第期

机译：Palbociclib（PAL）Pus Fulvestrant（F）对患有内分泌激素受体阳性（HR +）的地理区域，人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）的疗效和来自帕拉马的患者 - 3.
2. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 425, 2016) [J] . Cristofanilli M., Turner N. C., Bondarenko I The lancet oncology . 2016,第4期

机译：Fulvestrant加palbociclib与fulvestrant加安慰剂治疗先前接受内分泌治疗（PALOMA-3）进展的激素受体阳性，HER2阴性转移性乳腺癌：多中心，双盲，3期随机对照试验的最终分析（第17卷，第425页，2016年）
3. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J] . Cristofanilli Massimo, Turner Nicholas C., Bondarenko Igor, The lancet oncology . 2016,第4期

机译：Fulvestrant加palbociclib与fulvestrant加安慰剂治疗先前接受内分泌治疗（PALOMA-3）进展的激素受体阳性，HER2阴性转移性乳腺癌：多中心，双盲，3期随机对照试验的最终分析
4. Fabrication of Smart Anti-Integrin Conjugated PEGulated Cationic Protein Nanocarriers for Treatment of HER2 Breast Cancers [C] . Rethavathi Janarthanam, Narasimhan Srinivasan, Vijayakumar Bommaraj International Molecular Medicine Tri-Conference. . 2016

机译：智能抗整合蛋白共轭阳离子蛋白纳米载体的制备用于治疗HER2乳腺癌
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Exemestane and Everolimus combination treatment of hormone receptor positive HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity efficacy and safety [O] . Ferdinando Riccardi, Giuseppe Colantuoni, Anna Diana, -1

机译：依西美坦和依维莫司联合治疗激素受体阳性HER2阴性转移性乳腺癌：对坎帕尼亚地区（意大利南部）的9个癌症中心的回顾性研究重点是活性疗效和安全性
7. PCN23 Comparison Between Everolimus (Afinitor®) and Chemotherapy Agents (Capecitabine, Docetaxel and Doxorubicin) for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer [O] . Vieira J., Chandiwana D., Taylor M., 2013

机译：依维莫司（Afinitor®）与化学治疗剂（卡培他滨，多西他赛和阿霉素）治疗激素受体阳性（HR +）HER2阴性（HER2–）晚期或转移性乳腺癌的PCN23比较

PCN11 An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅